Related Experiment Video
Updated: Jan 4, 2026

Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
[Severe bleeding with antiplatelet therapy: What to do?]
Guillaume Cayla1, Luc Cornillet1, Bertrand Ledermann1
1Université de Montpellier, CHU de Nîmes, service de cardiologie, 30029 Nîmes, France.
Insights
Dual antiplatelet therapy, combining aspirin and a P2Y12 inhibitor, is crucial for coronary artery disease. Managing bleeding complications requires careful risk assessment and often involves stopping dual antiplatelet therapy.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Dual antiplatelet therapy (DAPT) is standard for acute coronary syndrome and following percutaneous coronary intervention.
- Aspirin and P2Y12 inhibitors are key components of DAPT.
- Bleeding is the most common complication, ranging from minimal to severe.
Purpose of the Study:
- To review the management of bleeding complications in patients on dual antiplatelet therapy.
- To emphasize the importance of individualized risk assessment for DAPT duration.
Main Methods:
- Literature review on antiplatelet therapy in coronary artery disease.
- Analysis of current guidelines for managing bleeding complications.
Main Results:
- Optimal DAPT duration is determined by patient-specific ischemic and bleeding risks.
- Severe bleeding necessitates interruption of DAPT in most cases.
- Individualized bleeding risk assessment is critical.
Conclusions:
- Effective management of bleeding complications is essential for patient safety.
- DAPT interruption is frequently required for severe bleeding events.
- Balancing ischemic protection and bleeding risk is paramount in DAPT management.
Abstract:
Antiplatelet therapy is the cornerstone of coronary artery disease treatment and prevention. Combination of aspirin and P2Y12 inhibitor is recommended after acute coronary syndrome and after elective percutaneous coronary intervention. The optimal duration of dual antiplatelet therapy depends on the individual ischemic and bleeding risk of the patient. Bleeding on dual anti platelet therapy remains the most frequent complication of antiplatelet therapy even is mostly minimal or moderate. Beyond individualized evaluation of patients' bleeding risk, management of patients with severe bleeding complications is a challenging situation and requires general and specific recommendations with interruption of the dual antiplatelet therapy in the vast majority of the cases.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
Peripheral Artery Disease III: Interprofessional Care

